AdobeStock_167064924Crop1_revrs.jpg

Clinical Studies to Demonstrate Tolperisone Benefit: Relief from Acute, Painful Muscle Spasms

CURRENT STUDIES

PHASE 3:

RESUME_1_Logo.png

The Phase 3, RESUME-1 clinical study was initiated in December 2020. The study will enroll ~1,000 patients and will assess tolperisone 50mg, 100mg, 200mg three times per day compared to placebo for 14 days of treatment. Top-line results are expected in Q4 2021.

PHASE 3:

RESUME_2_Logo.png

The Phase 3, RESUME-2 clinical study will initiate following completion of RESUME-1.

COMPLETED STUDIES

PHASE 1: CNS Effects Study   

The Phase 1 study, utilizing a validated driving test, confirmed that tolperisone does not impair driving performance. In addition, tolperisone does not appear to cause sleepiness, a side effect often associated with currently available skeletal muscle relaxants.

  • Tolperisone demonstrated non-inferiority compared to placebo

  • Cyclobenzaprine exceeded pre-established non- inferiority margin on all three days

PHASE 2: STAR Study

The STAR Study demonstrated that tolperisone was well-tolerated and did not increase sleepiness over placebo. The results enable Neurana to advance tolperisone to Phase 3 clinical studies in 2020.  

PHASE 1: Driving Study 

The Phase 1 driving simulation study demonstrated that tolperisone was similar to placebo in driving performance. In comparison, cyclobenzaprine, a commonly used muscle relaxant, significantly impacted driving performance. Most individuals on cyclobenzaprine performed similar to those with a blood alcohol concentration above 0.05%, which is considered above the legal limit in most states. In addition, most patients on cyclobenzaprine were unaware of their impairment.

 
 
 
 
 
 

NO IMPACT ON COGNITION WITH TOLPERISONE

In a simulated driving

study, tolperisone performed similar to placebo and with less impairment than cyclobenzaprine

 

The exact mechanism of action of tolperisone is not fully understood

No binding activity directed to benzodiazepine receptor

No opioid binding activity; no abuse potential

Sodium AND Calcium Blocking Mechanism

Tolp_MOA_callout_grn.png
Tolp_MOA_callout_blu.png

DUAL MECHANISM FOR MUSCLE SPASM & PAIN RELIEF

TolperisonBlocker_edited.png